NM_000263.4:c.461T>G
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000263.4(NAGLU):c.461T>G(p.Ile154Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000205 in 1,461,878 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000263.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NAGLU | NM_000263.4 | c.461T>G | p.Ile154Arg | missense_variant | Exon 2 of 6 | ENST00000225927.7 | NP_000254.2 | |
NAGLU | XM_024450771.2 | c.518T>G | p.Ile173Arg | missense_variant | Exon 3 of 7 | XP_024306539.1 | ||
NAGLU | XM_047436138.1 | c.-79+820T>G | intron_variant | Intron 1 of 4 | XP_047292094.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 35
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251392Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135906
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461878Hom.: 0 Cov.: 58 AF XY: 0.00000275 AC XY: 2AN XY: 727244
GnomAD4 genome Cov.: 35
ClinVar
Submissions by phenotype
Mucopolysaccharidosis, MPS-III-B Pathogenic:1Uncertain:1
Variant summary: NAGLU c.461T>G (p.Ile154Arg) results in a non-conservative amino acid change located in the Alpha-N-acetylglucosaminidase, tim-barrel domain (IPR024240) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251392 control chromosomes. c.461T>G has been reported in the literature in individuals affected with Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome B) (Lee-Chen_2002, Lin_2018). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function indicating a severe decrease in enzyme activity when compared to Wildtype (Clark_2018, Lee-Chen_2002). The following publications have been ascertained in the context of this evaluation (PMID: 30070758, 29979746, 11836372). Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. One submitter classified the variant as likey pathogenic, and one submitter classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
- -
Mucopolysaccharidosis, MPS-III-B;C5569050:Charcot-Marie-Tooth disease axonal type 2V Pathogenic:1
This sequence change replaces isoleucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 154 of the NAGLU protein (p.Ile154Arg). This variant is present in population databases (rs770684838, gnomAD 0.006%). This missense change has been observed in individual(s) with mucopolysaccharidosis type IIIB (PMID: 11836372, 30070758). ClinVar contains an entry for this variant (Variation ID: 558352). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NAGLU protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects NAGLU function (PMID: 11836372, 29979746). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at